Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain price value?
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government shutdown may soon conclude.
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level.
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit.
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing.
